- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01651299
Copperhead Envenomation Observational Study
May 10, 2013 updated by: BTG International Inc.
Observational Study of Recovery From Copperhead Snake Envenomation
The primary objective of the study is to evaluate the responsiveness and utility of several clinical outcome assessments in the setting of copperhead snakebite.
The secondary objective is to characterize the clinical course of signs, symptoms and impairment during the recovery phase of copperhead snakebite.
Study Overview
Status
Completed
Conditions
Detailed Description
This observational study will document the patient's recovery from copperhead snakebite.
All care provided will be at the discretion of the treating physician in accordance with the local standard of care.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Chandler Medical Center
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- LSU Health Sciences Center
-
-
Michigan
-
Jackson, Michigan, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
St. Louis, Missouri, United States, 76104
- Washington University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Medical Center
-
Greenville, North Carolina, United States, 27834
- Vidant Health
-
-
Texas
-
Bryan, Texas, United States, 77802
- St. Joseph Regional Health Center
-
Ft. Worth, Texas, United States, 76104
- Harris Methodist Hospital
-
Temple, Texas, United States, 76508
- Scott and White Hospital
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia, Blue Ridge PC
-
Richmond, Virginia, United States, 23219
- Virginia Commonwealth University Richmond
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Males and non-pregnant females at least 18 yrs of age with evidence of copperhead envenomation on an extremity distal to the knee or elbow that present for care at a health care facility within 24 hours of envenomation.
Description
Inclusion Criteria:
- Envenomation by a copperhead snake
- Presentation for care at a health care facility within 24 hrs of envenomation
- Envenomation on an extremity distal to the knee or elbow
- Clinical evidence of venom effect (limb swelling and/or tenderness)
- Enrollment can be completed within 48 hrs of envenomation prior to discharge
- Patient is willing and able to complete follow-up schedule of assessments
- Patient is able to read, comprehend and sign IRB approved informed consent
- Patient is able to read and comprehend written assessment tools
- Patient is at least 18 yrs old
- Patient is sober, competent and able to complete verbal and written informed consent
Exclusion Criteria:
- Patient is pregnant or breastfeeding
- Patient is a prisoner
- Patient has distracting injury, condition with acute pain or functional impairment, and/or is unable to make a reliable self-report of status
- Patient has had previous snake envenomation to any body area within 30 days prior to screening/enrollment, regardless of whether antivenom was administered
- Patient had an acute traumatic or medical event, surgery, or exacerbation of pre-existing medical or surgical condition effecting the envenomated extremity within 30 days prior to screening/enrollment
- Patient has participated in a clinical study involving and investigational pharmaceutical product or device within 3 months prior to screening that may have impact on clinical outcomes of snakebite
- Patient has previously participated in this study
- Patient is, in the investigator's opinion, otherwise unsuitable for participation. Note: Treatment with antivenom prior to eligibility evaluation is not an exclusion criterion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient Global Assessment of Recovery (PGAR)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Numeric Pain Rating Scale (NPRS)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Numeric Swelling Score (NSS)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
SF36v2 (Acute Version)
Time Frame: Time of Discharge, Day 7, Day, 14, Day 21, and Day 28
|
Time of Discharge, Day 7, Day, 14, Day 21, and Day 28
|
Swelling Figure-of-8 Measurement
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Grip Strength
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Walking Speed
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Patient Global Impression of Change (PGIC)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Return to Work/School/ADLs
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
|
Day 3, Day 7, Day 14, Day 21, and Day 28
|
Patient-Specific Functional Scale (PSFS)
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
|
Day 3, Day 7, Day 14, Day 21, and Day 28
|
WPAI:SHP V2
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
|
Day 3, Day 7, Day 14, Day 21, and Day 28
|
Disorders of the Arm, Shoulder, and Hand (DASH)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Lower Extremity Functional Scale
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
July 25, 2012
First Submitted That Met QC Criteria
July 26, 2012
First Posted (Estimate)
July 27, 2012
Study Record Updates
Last Update Posted (Estimate)
May 13, 2013
Last Update Submitted That Met QC Criteria
May 10, 2013
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTG-PR005-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Copperhead Snake Envenomation
-
Wake Forest University Health SciencesTerminatedSnake EnvenomationUnited States
-
BTG International Inc.CompletedSnake EnvenomationUnited States
-
Ophirex, Inc.Premier Research Group plcCompletedSnakebites | Envenoming | Envenoming, Snake | Envenomation, SnakeUnited States, India
-
Jubilee Mission Medical College and Research InstituteCompletedEnvenomation, Snakebite | EnvenomationIndia
-
Postgraduate Institute of Medical Education and...CompletedInvasive Mechanical Ventilation | Snake Envenomation | Adaptive Support VentilationIndia
-
University Hospital Center of MartiniqueUniversity Hospital, LilleNot yet recruitingHemorrhage | Coagulopathy | Thrombi | Snake Envenomation
-
Institut PasteurCentre Pasteur du Cameroun; Cameroon Society of Epidemiology (CaSE); Centre International... and other collaboratorsCompleted
-
Haffkine Bio-Pharmaceutical Corporation Ltd.Completed
-
University of ArizonaCompletedCoral Snake Bite | Toxic Effect of Coral Snake VenomUnited States